Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

bi 201335

bi 201335 is a hepatitis c virus serine protease, ns3/ns4a inhibitor.

NMPA: clinical trials
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — bi 201335
Class
—
Route
—
Patents
0
Programs
3
Data quality
0.70
← All drugs Search patents Pipeline programs Drug news hub Event calendar

Quick answer

bi 201335 is a hepatitis c virus serine protease, ns3/ns4a inhibitor.

Key facts

INN bi 201335
Mechanism Hepatitis C virus serine protease, NS3/NS4A inhibitor
Target Hepatitis C virus serine protease, NS3/NS4A

Mechanism of action

Hepatitis C virus serine protease, NS3/NS4A inhibitor

Primary target: Hepatitis C virus serine protease, NS3/NS4A

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Search pipeline
  1. BI 201335 Phase 3 · Boehringer Ingelheim · Hepatitis C
  2. BI 201335 Phase 3 · Boehringer Ingelheim · Hepatitis C, Chronic
  3. domestic polysaccharide superparamagnetic iron oxide nanoparticle Phase 1 · First People's Hospital · Chronic Kidney Diseases

Related & competitor drugs

Browse all drugs
  1. telaprevir Antiinfectives for systemic use (J05)
  2. boceprevir Antiinfectives for systemic use (J05)
  3. glecaprevir Antiinfectives for systemic use (J05)
  4. simeprevir sodium Hepatitis C virus serine protease, NS3/NS4A inhibitor
  5. faldaprevir Antiinfectives for systemic use (J05)
  6. asunaprevir Hepatitis C virus serine protease, NS3/NS4A inhibitor

Frequently asked questions

What is bi 201335?

bi 201335 is a hepatitis c virus serine protease, ns3/ns4a inhibitor.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.